View Older Stories View More Recent Stories

Mar 5, 2019 06:59AM Bristol-Myers Squibb to Take Part in the Cowen and Company 39th Annual Health Care Conference
Feb 28, 2019 12:00PM Bristol-Myers Squibb (BMY) Responded to Starboard's Letter, Confident in Combination with Celgene (CELG)
Feb 28, 2019 11:59AM Bristol-Myers Squibb Issues Statement in Response to Starboard’s Letter
Feb 22, 2019 04:49PM Bristol-Myers Squibb Announces Filing of Definitive Proxy Statement in Connection with Proposed Merger with Celgene
Feb 20, 2019 09:02AM Bristol-Myers Squibb (BMY) Provides Update on Pending Transaction with Celgene (CELG), Says Remains on Track to Close in Q3
Feb 20, 2019 09:00AM Bristol-Myers Squibb Provides Update on Pending Transaction with Celgene
Feb 14, 2019 05:00PM Bristol-Myers Squibb (BMY) Reports Opdivo (nivolumab) Plus Yervoy (ipilimumab) Shows Response in Pre-Treated Patients with Metastatic Castration-Resistant Prostate Cancer
Feb 14, 2019 04:00PM Opdivo (nivolumab) Plus Yervoy (ipilimumab) Shows Response in Pre-Treated Patients with Metastatic Castration-Resistant Prostate Cancer
Feb 11, 2019 05:05PM Bristol-Myers Squibb (BMY) Announces Opdivo Plus Low-Dose Yervoy Demonstrates Continued Survival Benefit at 30-Month Follow-up in Patients with Previously Untreated Advanced or Metastatic RCC
Feb 11, 2019 05:00PM Opdivo (nivolumab) Plus Low-Dose Yervoy (ipilimumab) Demonstrates Continued Survival Benefit at 30-Month Follow-up in Patients with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
Feb 11, 2019 07:00AM Bristol-Myers Squibb (BMY) Announces EC Approval for its Sprycel in Combination with Chemotherapy for Treatment of Pediatric Patients with Newly Diagnosed Ph+ ALL
Feb 11, 2019 06:59AM European Commission Approves Bristol-Myers Squibb’s Sprycel (dasatinib) in Combination with Chemotherapy for Treatment of Pediatric Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acu
Feb 7, 2019 06:59AM Bristol-Myers Squibb to Take Part in Guggenheim Healthcare Talks Idea Forum
Jan 24, 2019 06:59AM Bristol-Myers Squibb Announces Time Change for Q4 Earnings Results Conference Call
Jan 24, 2019 06:59AM Bristol-Myers Squibb Reports Fourth Quarter and Full Year Financial Results
Jan 14, 2019 04:20PM Bristol-Myers Squibb (BMY) Announces European Commission Approval for Opdivo (nivolumab) Plus Low-Dose Yervoy (ipilimumab)
Jan 14, 2019 04:15PM European Commission Approves Opdivo (nivolumab) Plus Low-Dose Yervoy (ipilimumab) for First-Line Treatment of Patients with Intermediate- and Poor-Risk Advanced Renal Cell Carcinoma
Jan 5, 2019 11:07AM Bristol-Myers Squibb to Participate in the 37th Annual J.P. Morgan Healthcare Conference
Jan 3, 2019 07:04AM UPDATE: Bristol-Myers Squibb (BMY) Announces FY19 EPS Guidance of $4.10-$4.20, Above Consensus of $4.07
Jan 3, 2019 06:59AM Bristol-Myers Squibb (BMY) to Acquire Celgene Corp. (CELG) for Approx. $74B
Jan 3, 2019 06:58AM Bristol-Myers Squibb Provides 2019 EPS Guidance
Jan 3, 2019 06:58AM Bristol-Myers Squibb to Acquire Celgene to Create a Premier Innovative Biopharma Company
Jan 2, 2019 04:25PM Bristol-Myers Squibb’s Sprycel® (dasatinib) Tablets Now Approved in Combination with Chemotherapy in Certain Pediatric Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
Dec 19, 2018 05:48AM Bristol-Myers Squibb (BMY) Reports Offer from Taisho Pharmaceutical Holdings Co., Ltd to Purchase UPSA Consumer Health Business for $1.6B
Dec 19, 2018 03:30AM Bristol-Myers Squibb Announces Offer from Taisho Pharmaceutical Holdings Co., Ltd to Purchase UPSA
Dec 17, 2018 04:34PM Bristol-Myers Squibb (BMY) Announces Research Collaboration with Boston Medical Center to Investigate Markers of Immuno-Oncology Response & Resistance
Dec 17, 2018 04:30PM Bristol-Myers Squibb and Boston Medical Center Announce Research Collaboration to Investigate Markers of Immuno-Oncology Response and Resistance
Dec 17, 2018 07:00AM Bristol-Myers Squibb (BMY) Reports Positive CHMP Opinion Recommending Sprycel for Pediatric Patients with Newly Diagnosed Philadelphia Chromosome-Positive ALL
Dec 17, 2018 06:59AM Bristol-Myers Squibb and H3 Biomedicine Announce Research Collaboration to Advance Novel Therapeutics Leveraging H3’s RNA Splicing Platform
Dec 17, 2018 06:59AM Bristol-Myers Squibb Receives Positive CHMP Opinion Recommending Sprycel (dasatinib) for Pediatric Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
Dec 10, 2018 05:56AM Bristol-Myers Squibb (BMY), Vedanta Biosciences Report New Clinical Collaboration to Evaluate OPDIVO (Nivolumab) & VE800 in Patients with Advanced or Metastatic Cancers
Dec 10, 2018 02:00AM Bristol-Myers Squibb and Vedanta Biosciences Announce a New Clinical Collaboration to Evaluate OPDIVO® (nivolumab) and VE800 in Patients with Advanced or Metastatic Cancers
Dec 10, 2018 02:00AM Bristol-Myers Squibb and Vedanta Biosciences Announce a New Clinical Collaboration to Evaluate OPDIVO (Nivolumab) and VE800 in Patients with Advanced or Metastatic Cancers
Dec 6, 2018 04:15PM Bristol-Myers Squibb Announces Dividend Increase
Dec 5, 2018 06:59AM Bristol-Myers Squibb to Announce Results for Fourth Quarter 2018 on January 24
Dec 3, 2018 05:04PM Athene Announces Significant Pension Risk Transfer Transaction with Bristol-Myers Squibb
Dec 3, 2018 05:00PM Bristol-Myers Squibb to Transfer $3.8 billion in U.S. Pension Liabilities
Nov 29, 2018 04:30PM Bristol-Myers Squibb to Highlight New Data from Broad Oncology Portfolio at the 60th American Society of Hematology Annual Meeting
Nov 29, 2018 06:59AM Bristol-Myers Squibb to Take Part in Citi 2018 Global Healthcare Conference
Nov 26, 2018 04:32PM Bristol-Myers Squibb (BMY) Announces CheckMate -451 Study Did Not Meet Primary Endpoint of OS with Opdivo Plus Yervoy Vs. Placebo in SCLC
Nov 26, 2018 04:30PM Bristol-Myers Squibb Announces CheckMate -451 Study Did Not Meet Primary Endpoint of Overall Survival with Opdivo Plus Yervoy Vs. Placebo as A Maintenance Therapy in Patients with Extensive-Stage Smal
Nov 26, 2018 06:59AM Bristol-Myers Squibb Awards “Golden Tickets” for LabCentral to ReviveMed, Strand Therapeutics
Nov 20, 2018 06:59AM Bristol-Myers Squibb to Take Part in Evercore ISI HealthCONx Conference
Nov 15, 2018 04:34PM Bristol-Myers Squibb (BMY) Receives Positive CHMP Opinion on Approval of Opdivo Plus Low-Dose Yervoy as First-Line Treatment for Patients with RCC
Nov 15, 2018 04:30PM Bristol-Myers Squibb Receives Positive CHMP Opinion Recommending Approval of Opdivo® (nivolumab) Plus Low-Dose Yervoy® (ipilimumab) as First-Line Treatment for Patients with Intermediate- and Poor-R
Nov 7, 2018 06:59AM Bristol-Myers Squibb to Take Part in Credit Suisse 2018 Health Care Conference
Nov 6, 2018 04:36PM Bristol-Myers Squibb (BMY) Announces Approves Empliciti Plus Pomalidomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma
Nov 6, 2018 04:34PM U.S. Food and Drug Administration Approves Empliciti® (elotuzumab) Plus Pomalidomide and Dexamethasone, a New Immunotherapy Combination for Certain Patients with Relapsed or Refractory Multiple Myelo
Nov 5, 2018 07:00AM Bristol-Myers Squibb (BMY), Infinity Pharmaceuticals (INFI) Reports New Clinical Collaboration to Evaluate Opdivo (Nivolumab) in Combination with IPI-549 in Urothelial Cancer
Nov 5, 2018 06:59AM Bristol-Myers Squibb and Infinity Pharmaceuticals Announce a New Clinical Collaboration to Evaluate Opdivo (Nivolumab) in Combination with IPI-549 in Urothelial Cancer
View More Recent Stories View Older Stories